Background-The correlates of left ventricular (LV) substrate in arrhythmogenic right ventricular (RV) cardiomyopathy are largely unknown. Methods and Results-Thirty-two patients with arrhythmogenic RV cardiomyopathy (47±14 years; 6 women) were included. RV and LV dysplasia were defined from multidetector computed tomography and cardiac magnetic resonance imaging. Arrhythmias were characterized as right-sided or left-sided on 12-lead ECG recordings at baseline and during isoproterenol testing. In 14 patients, the imaging substrate was compared with voltage mapping and local abnormal ventricular activity. Imaging abnormalities were found in 32 (100%) and 21 (66%) patients on the RV and LV, respectively, intramyocardial fat on multidetector computed tomography being the most sensitive feature. LV involvement related to none of the Task Force criteria. Right-sided arrhythmias were more frequent than left-sided arrhythmias (P=0.003) although the latter were more frequent in case of LV involvement (P=0.02). The agreement between low voltage and fat on multidetector computed tomography was high on the RV when using either endocardial unipolar or epicardial bipolar data (κ=0.82 and κ=0.78, respectively) but lower on the LV (κ=0.54 for epicardial bipolar). LV local abnormal ventricular activity was found in all patients with LV involvement, and none of the others. The density of local abnormal ventricular activity within fat areas was similar between the RV and LV (P=0.57). Conclusions-LV substrate is frequent in arrhythmogenic RV cardiomyopathy, but poorly identified by current diagnostic strategies. Left-sided arrhythmias are more frequent in case of LV involvement. LV fat hosts the same density of local abnormal ventricular activity as RV fat, but is less efficiently detected by voltage mapping. These results support the need for alternative diagnostic strategies to identify LV dysplasia. (Circ Arrhythm Electrophysiol.
A rrhythmogenic right ventricular cardiomyopathy (ARVC) is a condition characterized by progressive fibrofatty replacement of the subepicardial layers of the ventricular myocardium. 1 This substrate results in the development of a complex heterogeneous scar, which increases susceptibility to ventricular arrhythmia and sudden cardiac death. 2 Although the dysplastic tissue predominantly involves the right ventricle (RV), left ventricular (LV) involvement is not uncommon. Its prevalence in patients with ARVC was reported as high as 75% in imaging studies, and ≤88% in histological studies. [3] [4] [5] As a majority of studies investigating the arrhythmogenic substrate in ARVC have focused on the RV, there is a relative paucity of data on the left-sided substrate. 2, 6, 7 The aim of the present study was to define the imaging and electrophysiological characteristics of the left-sided ARVC substrate.
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Methods
Population
From January 2009 to November 2014, consecutive patients referred for the diagnosis or the therapeutical management of ARVC were prospectively enrolled. The inclusion criterion was a definite ARVC diagnosis according to the modified 2010 Task Force recommendations. 8 Exclusion criteria were contraindications to contrastenhanced multidetector computed tomography (MDCT). All patients underwent a comprehensive diagnostic evaluation comprising clinical evaluation, ECG, signal-averaged ECG, 24-hour Holter, transthoracic echocardiography, and cardiac magnetic resonance (CMR) unless contraindicated. These studies were analyzed according to Task Force recommendations. Implantable cardioverter defibrillators were considered as a contraindication to CMR. Myocardial biopsy was not routinely performed. Genetic testing was not part of the study protocol, but available results from potential prior testing were considered for analysis. In addition, all patients underwent laboratory assessment of renal function, isoproterenol testing, and MDCT to assess intramyocardial fat. In a subpopulation referred for catheter ablation, electroanatomic maps were acquired and registered to imaging data. The study was approved by the Institutional Ethics Committee, and all patients provided informed consent.
Imaging
Contrast-enhanced ECG-gated cardiac MDCT was performed on a 64-slice CT scanner (SOMATOM Definition; Siemens Medical Solutions, Forchheim, Germany). CT angiographic images were acquired during the injection of 120-mL iomeprol 400 mg I/ mL (Bracco, Milan, Italy) using a biphasic injection protocol, ie, 60 mL contrast followed by 120 mL of a 50:50 mixture of saline and contrast at the rate of 5 mL/s. Images were reconstructed in a stack of 1-mm-thick slices encompassing the whole heart in shortaxis orientation. Image processing was performed using dedicated software (MUSIC software; LIRYC Institute, Bordeaux University/ Inria, Sophia Antipolis, France). Intramyocardial fat was defined as any myocardial voxel with attenuation less than −10 HU, based on previous validation versus contact mapping. 9 This substrate was segmented using an automated image processing method, as described previously, 9, 10 and distributed over a biventricular 16-segment model: the RV and LV free walls comprised 7 segments each (3 segments at basal and midventricular levels-ie, anterior, lateral, and inferiorand 1 segment at the apex), and the septum comprised 2 segments (basal and midventricular). CMR imaging was performed on a 1.5T system (Avanto; Siemens Medical Solutions, Erlangen, Germany). Cine imaging was performed using a steady state free precession sequence in 2 stacks of contiguous 6-mm-thick slices encompassing the whole ventricles in short-axis and 4-chamber orientations. RV and LV volumes and ejection fraction (EF) were quantified from cine images using Argus software (Siemens Medical Systems, Erlangen, Germany). Ventricular dilatation and systolic dysfunction were defined based on previously reported normal values in men and women on the LV 11 and RV. 12 Late gadolinium-enhanced imaging was performed 10 minutes after the injection of 0.2 mmol/kg gadoterate meglumine (Guerbet, Aulnay-sous-Bois, France) using a 3-dimensional (3D) turbo Fast Low Angle Shot sequence in 3 stacks of contiguous 6-mm-thick slices encompassing the whole ventricles in short-axis, 2-chamber, and 4-chamber orientations. Cine and late enhancement images were reviewed by 2 observers analyzing the images in consensus. On each RV and LV segment, regional wall motion was described as either normal or abnormal and regional fibrosis was described as either present or absent. After image analysis, LV involvement was considered present if ≥1 LV segments (excluding the 2 septal segments) exhibited fat on MDCT, fibrosis on CMR, or wall motion abnormalities on CMR. In addition, the transmural distribution of the left-sided substrate was characterized on both MDCT and late gadolinium enhancement CMR images. The LV substrate was defined as subepicardial when its largest surface was located on the epicardial side of the LV wall, subendocardial when its largest surface was located on the endocardial side, and intramural when its largest surface was located within midmyocardial layers. In addition, subendocardial, subepicardial, and intramural scars could be categorized as transmural if the substrate extended from the endocardium to the epicardium on at least 1 site.
Arrhythmia Characterization
In all patients, ventricular arrhythmias were characterized from 12-lead ECG recordings at baseline and during isoproterenol testing. Isoproterenol testing was performed after withdrawal of β-blockers, calcium channel blockers, and other antiarrhythmic agents for ≥5 half-lives. Equipment for cardiopulmonary resuscitation was readily accessible in the room during the test. A continuous infusion of isoproterenol at the rate of 45 μg/min was administered for 3 minutes, regardless of heart rate. The 12-lead ECG (recorded at 25 mm/s and 10 mm/mV) was continuously recorded from the beginning of infusion and until 10 minutes after the cessation of infusion. In case of ventricular tachycardia, the infusion was immediately stopped and a β-blocker (atenolol 5 mg for 1 minute) was injected intravenously. Each episode of single premature ventricular complex (PVC), run of nonsustained VT or sustained VT was analyzed to define the VT exit site. A V1-positive morphology was always defined as a left-sided exit. 13, 14 In addition, an R/S amplitude of ≥30% in V1 or V2 combined with a R-wave duration ≥50% of the total QRS duration in V1 was also considered as a left-sided exit. 15 A V1-negative morphology was defined as a right-sided exit.
13,14
Contact Mapping
Contact mapping was performed using a 3D mapping system (CARTO3; Biosense Webster, Diamond Bar, CA). Endocardial mapping was performed via a femoral venous approach, and all patients also underwent epicardial mapping via a subxyphoid approach. Highdensity substrate mapping was performed on complete epicardial (a fill threshold <15 for the entire epicardium was used) and RV endocardial surfaces with a multipolar catheter (PentaRay NAV; Biosense Webster). Endocardial and epicardial bipolar voltage maps were created using peak-to-peak amplitudes of <0.5 mV to indicate dense scar, from 0.5 to 1.5 mV to indicate borderzone on the endocardium, and from 0.5 to 1 mV to indicate borderzone on the epicardium. [16] [17] [18] In addition, endocardial and epicardial unipolar voltage maps were created using thresholds of <5.5 mV and <7.95 mV to define low voltage, respectively. [19] [20] [21] Besides voltage, all sites exhibiting local abnormal ventricular activity (LAVA), as defined previously, 22 were tagged on the substrate map. VT inducibility was tested at the beginning and at the end of the procedure from 2 pacing sites on RV apex and right ventricular outflow tract, using a decreasing pacing train (600-500-400 ms) and ≤3 extrastimuli. If hemodynamically tolerated, activation mapping and ablation were performed during VT. Differentiation between right-sided and left-sided VT exits was annotated. In case of unstable or poorly tolerated VT, the 12-lead ECG alone was used to define the exit site. Ablation was conducted using complete right-sided LAVA elimination and noninducibility of any
WHAT IS KNOWN
• Fibrofatty replacement can also occur on the left ventricle in patients with ARVC.
• Fibrofatty replacement is the structural substrate of scar-related reentrant tachycardia in ARVC.
WHAT THE STUDY ADDS
• LV intramyocardial fat is present on MDCT imaging in the majority of patients fulfilling the modified Task Force criteria for ARVC, mostly on lateral, inferior, and apical LV segments, and with a lower burden as compared to the RV.
• LV dysplasic substrate is poorly identified by imaging methods performed within the frame of Task Force recommendations, and relates to none of the Task Force criteria.
• LV fat hosts the same density of LAVA as RV fat, but is less efficiently detected by voltage mapping.
VT as procedural end points. Left-sided LAVA ablation was only conducted in case a left-sided VT was observed at baseline, during isoproterenol testing, or during the stimulation protocol.
Post Hoc Analysis
Intramyocardial fat areas were mapped onto endocardial and epicardial geometries as segmented from MDCT images. The resulting patient-specific 3D meshes were loaded in 3D mapping systems. The following anatomic landmarks were used to initiate pointbased registration between the imaging and the mapping geometries: coronary sinus, RV apex, and tricuspid annulus (3, 6, 9, and 12 o'clock). Registration was then refined using automatic surface registration. Once registration was achieved, myocardial fat and low voltage were distributed >3 separate segmentations: RV endocardium (9 segments including the septum), RV epicardium (7 segments), and LV epicardium (7 segments). In addition, areas of fat and low voltage were manually contoured, their extent being expressed in centimeter square. To minimize the effect of epicardial fat on low-voltage area measurements, the anterior interventricular sulcus and the AV grove (defined as the first centimeter from mitral and tricuspid annuli) were not considered for segmentation when contouring epicardial low-voltage areas. 23 The distribution of LAVA sites with respect to this substrate was analyzed, and the density of LAVA sites per centimeter square of substrate was assessed and compared between the RV and the LV. To avoid a double counting of LAVAs, 2 sites were considered different if the distance between both sites was >3 mm. In addition, the amplitude and delay of each LAVA signal were measured and compared between RV and LV LAVAs. LAVA amplitude was defined as the bipolar voltage of the near-field component of the signal, expressed in mV. LAVA delay was defined as the delay from QRS onset to the end of LAVA activity, expressed in millisecond.
Statistical Analysis
Continuous variables were expressed as mean±SD for normally distributed data or median (interquartile range, 25th-75th percentile) for non-normally distributed data. Categorical data were expressed as counts and percentages. Data were tested for normality by using the Kolmogorov-Smirnov test. Continuous variables were compared using independent-sample parametric (unpaired Student t test) or nonparametric tests (Mann-Whitney) depending on data normality. Categorical variables were compared using Fisher exact or χ 2 tests, as appropriate. The agreement between fat on MDCT and low voltage was assessed using Cohen κ coefficients, calculated sequentially for RV endocardium, RV epicardium, and LV epicardium and for bipolar and unipolar voltage measurements. Statistical analyses were performed using PASW Statistics 18 (version 18.0.0).
Results
Population Characteristics
Thirty-two patients (47±14 years; 6 women) were included. The characteristics of the studied population are shown in Table 1 . All patients had a definite ARVC diagnosis, with mean numbers of minor and major Task Force criteria of 2.1±1.2 and 1.9±1.2, respectively. The time since initial ARVC diagnosis was 36 (0-96) months. In addition to the complete ARVC diagnostic workup recommended by the Task Force, isoproterenol testing and MDCT were performed in all patients. CMR was performed in 22 (69%) of the patients (including 4 patients with implantable cardioverter defibrillator but with available MRI preformed <6 months before inclusion). Genetic testing was available in 20 (63%) patients and was found to be positive for PKP2 mutation in 9 (45%) of these patients. Other gene mutations were identified in 5 patients, including DSG2 (N=1), ACTN2 (N=1), TNNC1 (N=1), DSC2 (N=1), and TNEM43 (N=1). Fourteen (44%) patients were referred for VT ablation, and therefore included in the mapping substudy.
Imaging Findings
Imaging was positive for a major Task Force criterion in 18 (56%) patients, for a minor Task Force criterion in 6 (19%), and it was negative in 8 (25%). The characteristics of ARVC substrate on imaging are summarized in Table 2 . The distribution of fat on MDCT over the LV and RV walls is illustrated in Figure 1 . On the RV, fibrosis and wall motion abnormalities were found on CMR in 20 (91%) and 21 (95%) patients, respectively, whereas fat was found on MDCT in 32 (100%) patients. The extents of RV fat on MDCT and RV wall motion abnormalities on CMR were higher than the extent of RV fibrosis on CMR (P<0.0001 and P<0.0001, respectively). The extent of RV fat on MDCT was higher than the extent of RV wall motion abnormalities (P=0.001). On the LV, fibrosis and wall motion abnormalities were found on CMR in 14 (64%) and 2 (9%) patients, respectively, whereas fat was found on MDCT in 21 (66%) patients. The extent of LV fat on MDCT and LV fibrosis on CMR was higher than the extent of LV wall motion abnormalities (P<0.0001 and P<0.0001, respectively). No difference was found between the extent of LV fat on MDCT and LV fibrosis on CMR (P=0.33). LV involvement was present in 21 (66%) of the studied population. Examples of LV involvement on imaging are shown in Figure 2 .
Clinical Correlates of LV Involvement
Baseline clinical characteristics in patients with and without LV involvement are compared in Table 1 . LV involvement related to none of the Task Force criteria. We found no association between the presence of PKP2 gene mutation and the presence of LV substrate. The only characteristic that differed between patients with versus without LV involvement was LVEF (56±8 versus 63±8%, respectively, P=0.02), and a fair correlation was found between LVEF and the extent of LV substrate on imaging (R=−0.52; P=0.002). However, LVEF was significantly altered (ie, <56%) in only 8 (38%) patients with LV substrate. The analysis of spontaneous and isoproterenol-induced arrhythmias is shown in Table 3 . In the whole population, right-sided PVCs were more frequent than leftsided PVCs (P=0.003). The number of right-sided PVCs was not different between patients with versus without LV involvement (P=0.25). Patients with LV involvement showed a higher number of left-sided PVCs (P=0.02). In the whole population, a total of 39 VTs were observed, either spontaneously or during isoproterenol testing. Three (8%) of these VTs were polymorphic and, therefore, could not be characterized. Among the 36 monomorphic VTs, right-sided VTs were more frequent than left-sided VTs (34 right-sided VTs in 24 [75%] patients versus 2 left-sided VTs in 2 [6%] patients; P<0.0001). These 2 left-sided VTs were observed in patients with LV involvement on imaging, but the association between LV involvement and left-sided VT was not significant (P=0.33). December 2015
Electrophysiological Characteristics of the LV Substrate
The population undergoing electrophysiological study was composed of 14 patients (43±16 years; 1 woman). LV involvement was present on imaging in 9 (64%) patients. All patients underwent high-density mapping of the RV endocardium (mapping density, 497±264 points per map) and biventricular epicardium (mapping density, 567±261 points per map). The agreement between low voltage and intramyocardial fat on imaging is shown in Table 4 . The higher agreement was found when using RV endocardial unipolar and RV epicardial bipolar data. Lower agreements were found on the LV. Contact mapping characteristics of LV and RV fat, as defined by MDCT, are compared in Table 5 . When compared with RV fat, LV fat was found to be smaller (P<0.0001), and less efficiently detected on voltage mapping (P=0.02 on both bipolar and unipolar voltage data). Although the number of LAVAs was higher on the RV than on the LV (P<0.0001), LAVAs were found within LV fat areas in all patients with LV involvement, and the density of LAVA within the fatty substrate defined 
001).
An example of LV substrate on contact mapping and imaging is shown in Figure 3 .
Procedural Results
In the population of 14 patients who underwent an EP study, a total of 23 spontaneous VTs had been documented (22 right sided and 1 left sided), a total of 5 VT morphologies had been induced by isoproterenol (5 right-sided, 3 of which were consistent with the morphology of spontaneous VTs), and a total of 27 VT morphologies were induced by programmed ventricular stimulation (26 right sided and 1 left sided, 13 of which were consistent with the morphology of spontaneous VTs). The left-sided VT induced by programmed stimulation was from a different patient than the left-sided VT induced by isoproterenol (this latter patient did not undergo an EP study). A mean of 2.0±0.8 VTs was induced, all of which with RV morphology except for 1 nonclinical left-sided VT in 1 patient. A mean of 107±49 LAVAs were identified during sinus rhythm, including LV LAVAs in all 9 patients with LV substrate on imaging, and in none of the 5 patients with no LV substrate on imaging. After a mean of 29±9 min of radiofrequency ablation (endocardial ablation, 20±6 min and epicardial ablation, 9±7 min), complete RV LAVA elimination could be achieved in 8 of 14 (57%) patients, and noninducibility of VT in 13 of 14 (93%) patients, the remaining patient being not tested because the VT induced at baseline was poorly tolerated. In the patient with inducible left-sided VT, LV LAVA could be successfully eliminated by epicardial ablation, resulting in the loss of VT inducibility. After a median follow-up of 19 months, VT recurrence was observed in 5 of 14 (36%) patients, with no difference between patients with versus without LV involvement (33% versus 40%, respectively; P=0.82).
Discussion
The main findings of this study are that (1) LV intramyocardial fat is present on imaging in the majority of patients with ARVC fulfilling the modified Task Force criteria, mostly on lateral, inferior, and apical LV segments, and with a lower burden than the RV, (2) LV involvement relates to none of the Task Force criteria although mild LV systolic dysfunction and left-sided arrhythmias are more frequent, (3) LV fat hosts the same density of LAVA as RV fat, but is less efficiently detected by voltage mapping. *The extent of fibrosis, wall motion abnormalities, and fat are based on 9 segments on the RV (including septal segments) and 7 segments on the LV (excluding septal segments).
†Applies to patients with LV substrate on imaging (N=14 on CMR; N=21 on MDCT). 
Distribution of Structural Substrate in ARVC
This study shows that RV fat in patients with ARVC predominates in basal lateral, basal inferior, and midlateral segments and is rarely found in the septum. The method used to segment intramyocardial fat from MDCT is based on previous validation studies demonstrating good correlation with contact mapping data 9 and Task Force criteria. 10 The distribution of RV fat is consistent with previous histological 3,24 and contact mapping studies. 18, 25 In the current study, RV substrate was also assessed with the use of MRI. Results indicate that wall motion abnormalities on cine images are more efficient in describing the extent of RV dyplasia than fibrosis on late gadolinium enhancement, which is likely to be because of spatial resolution issues when studying fibrosis on the thin RV wall. 5, 26, 27 In the present study, RV wall motion abnormalities were found in 95% of the patients, but imaging was positive for a major or minor Task Force criterion in only 75% of the patients. This indicates that RV volume and EF cutoff values recommended by the Task Force are the factors limiting imaging sensitivity. 8 In the present study, LV fat was found on MDCT in 66% of patients with ARVC, mostly in inferior, lateral, and apical segments, and with a lower burden than the RV. When analyzing its transmural location on CMR and MDCT, LV substrate was found to be predominant of subepicardial or intramural location, and rarely transmural. The prevalence of LV substrate is consistent with previous imaging reports, 4, 5, 28, 29 and superior to the one usually reported in mapping studies. 5, 30 The regional distribution and transmural location of the LV substrate is also consistent with previous studies. [31] [32] [33] The lower burden of LV substrate than that of the RV might be explained by a selection bias, patients being included in the present study based on Task Force criteria, which are designed to identify RV dysplasia. This outlines the limitations of the current diagnostic strategy in detecting LV variants of arrhythmogenic dysplasia/cardiomyopathy. 7 MRI results indicate that as opposed to the RV substrate, fibrosis on late gadolinium enhancement is more efficient in detecting LV dysplasia than wall motion abnormalities, which are usually absent. This result suggests that although the use of tissue characterization methods is not recommended by the Task Force, these are of great value to detect LV involvement in ARVC. 31 
Clinical Correlates of LV Involvement in ARVC
Our results show that LV involvement in ARVC relates to none of the Task Force criteria. This can be explained by the fact that Task Force criteria are essentially dependent on the burden of RV substrate. Indeed, diffuse RV dysplasia can be seen in the absence of LV involvement, and conversely LV variants of arrhythmogenic cardiomyopathy with minimal RV involvement have been reported. 31 In the present study, we found a fair inverse correlation between the presence of LV fat and LVEF. However, significant LV systolic dysfunction was only present in 38% of the patients with LV involvement. This further outlines the need for tissue characterization methods to identify LV dysplasia, which is often nontransmural and therefore has limited impact on global and regional systolic function. Genetic testing was available in 20 patients, and no relationship was found between PKP2 gene mutation and the presence of LV dysplasia. Other less prevalent gene mutations could not be analyzed because of sample size limitations. In the present study, arrhythmogenicity was assessed from 12-lead ECG recordings at baseline and during isoproterenol testing. The rationale to use isoproterenol testing was that the ARVC substrate is known to show explosive response to isoproterenol, 34 and we hypothesized that an increased sensitivity would be of value to detect left-sided arrhythmias, which were expected to be less frequent when compared with right-sided arrhythmias. As expected, our results show that right-sided PVCs are more frequent than left-sided PVCs in ARVC although left-sided PVCs are more frequent in patients with LV involvement on imaging than in those without. This demonstrates that LV involvement is associated with a certain degree of arrhythmogenicity. However, we found no significant difference in the prevalence of left-sided VTs, which is likely because of the limited sample size (only 2 left-sided VTs were observed, both in patients with LV involvement).
Electrophysiological Characteristics of the LV Substrate in ARVC
This study shows that RV endocardial voltage mapping is more accurate in detecting RV dysplasic substrate when using unipolar than bipolar data. This is consistent with a previous study and has been explained by the limitation of vendocardial bipolar voltage in detecting subepicardial scar, whereas unipolar is more sensitive to distant substrate. 17, 21 Conversely, RV epicardial voltage mapping shows a higher agreement with MDCT-derived fat when using bipolar than using unipolar data. This is also consistent with previous reports and can be explained by an overestimation of the substrate on unipolar voltage data, because of epicardial fat interposition. 9, 35 To our knowledge, this study is the first to report on the accuracy of voltage mapping to detect LV dysplasia. Our results show that voltage mapping is less efficient on the LV than on the RV. This can be explained by the fact that fat is usually nontransmural on the LV, resulting in falsenegative voltage measurements because of far-field signal from the adjacent healthy myocardium. The poor sensitivity of voltage mapping in detecting subepicardial scar on the LV is likely responsible for the underestimation of left-sided ARVC involvement in contact mapping studies. However, an accurate delineation of the diseased LV myocardium would be of value because our results show that the prevalence and density of LAVA within LV fat areas are similar to those observed on the RV. Therefore, there seems to be no difference between RV and LV fat in terms of arrhythmogenicity, and the higher prevalence of right-sided arrhythmias in ARVC patients seems to be merely the consequence of a selection based on Task Force criteria, in which the RV substrate only is targeted. Of note, LAVA characteristics differed between the RV and LV. LV LAVA particularly showed shorter delays and were more often found within the far-field QRS complex. We believe that this is because of differences in the structural environment of left-and rightsided substrates in ARVC. Our results indicate that LV scar in patients fulfilling Task Force criteria for ARVC is usually nontransmural and of limited size when compared with RV scar. Therefore, in this population, severe delay and fractionation are rarely encountered within LV scars, probably because LAVA sites are coupled to the remote myocardium by shorter channels of slow conduction.
Limitations
The first limitation of this study is the absence of predominantly LV forms of arrhythmogenic dysplasia. This is the consequence of a selection based on Task Force criteria, which was mandatory in the absence of alternate diagnostic strategy focusing on LV dysplasia. We acknowledge that the absence of endomyocardial biopsy is a limit to this study. Indeed, evidence of LV fibrofatty replacement on histology might have been used to identify LV variants. However, our results show that LV dysplasia rarely involves the septum but rather predominates in the subepicardial layers of the LV free wall, and performing biopsies on such locations would be extremely challenging. This outlines the diagnostic dilemma in identifying LV variants of arrhythmogenic cardiomyopathy, which are likely to be largely underestimated by current diagnostic approaches, and easily mistaken on imaging for other types of cardiac diseases characterized by subepicardial scar, such as postmyocarditis, sarcoidosis, dilated cardiomyopathy, or idiopathic myocardial fibrosis. 36, 37 Because imaging, clinical, and electrophysiological characteristics show substantial limitations, this differential diagnosis might be assisted by genetic testing in the near future. Unfortunately, in the present study, genotyping was only available in 20 patients, and PKP2 was the only gene mutation sufficiently prevalent to be analyzed. 38 Therefore, additional research is desirable to look for a potential specific genetic substrate associated with LV dysplasia. Of note, this study cannot assess the sensitivity and specificity of Task Force criteria to detect LV substrate because patients who did not meet these criteria were not considered for inclusion. However, our results suggest that among patients with a definite diagnosis of ARVC, no individual Task Force criteria is able to distinguish those with from those without LV involvement. Another limitation is that the characterization of the RV substrate was based on combined endocardial and epicardial mapping data, whereas we only mapped the LV substrate epicardially. However, the LV substrate being usually nontransmural on imaging, we hypothesized that few electrophysiological substrate would be present on LV endocardium. Finally, arrhythmogenicity was not consistently assessed in the studied population because programmed ventricular stimulation was only performed in the 14 patients undergoing a mapping and ablation procedure.
Conclusions
LV intramyocardial fat is present on imaging in the majority of patients fulfilling the modified Task Force criteria for ARVC, mostly on lateral, inferior, and apical LV segments, and with a lower burden than the RV. This substrate is poorly identified by imaging methods performed within the frame of Task Force recommendations. LV involvement relates to none of the Task Force criteria although mild LV systolic dysfunction and left-sided arrhythmias are more frequent. LV fat hosts the same density of LAVA as RV fat, but is less efficiently detected by voltage mapping. These results support the need for alternate diagnostic strategies to identify LV dysplasia.
